お問い合わせ English

Overseas Invited Speakers

Roy S. Herbst

Roy S. Herbst
Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine, USA

SY1 : Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer




Jin Mo Goo

Jin Mo Goo
Professor of Radiology, Department of Radiology, Seoul National University College of Medicine, Korea

SY4 : Globalization and Future of Lung Cancer Screening




David R. Gandara

David R. Gandara
Professor of Medicine Emeritus, Division of Hematology/Oncology, University of California, Davis School of Medicine Director, Thoracic Oncology, Senior Advisor to the Director, UC Davis Comprehensive Cancer Center, USA

SY5 : Genome Medicine and Translational Research




Aaron Hata

Aaron Hata
Assistant Professor of Medicine at Massachusetts General Hospital, Principal Investigator in the MGH Center for Cancer Research, and Associate Member of the Broad Institute of Harvard and MIT, USA

SY5 : Genome Medicine and Translational Research




Roman Thomas

Roman Thomas
University of Cologne, Germany

SY6 : Basics in Cancer Biology: Overview of New Targets




Erik Thunnissen

Erik Thunnissen
Department of Pathology, Amsterdam University Medical Center, Netherland

SY2 : An Updated Approach to the Pathological Diagnosis of the Lung Cancer




Michael Thomas Milano

Michael Thomas Milano
University of Rochester School of Medicine and Dentistry Department of Radiation Oncology and Wilmot Cancer Institute, USA

SY9 : Radiotherapy for Oligometastasis




Bruce E. Johnson

Bruce E. Johnson
Chief Clinical Research Officer, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School, USA

SY10 : Treatment of EGFR-Mutated and ALK-Fusion Positive Lung Cancer




Benjamin Solomon

Benjamin Solomon
Medical oncologist at the Peter MacCallum Cancer Centre Professor of Medicine at the University of Melbourne, Australia

SY13 : Treatment of Driver Mutation Positive Lung Cancer, Except for EGFR and ALK (include Ras/RAF)




Daniel Shao-Weng Tan

Daniel Shao-Weng Tan
Senior Consultant of Division of Medical Oncology, Principal Investigator of Cancer Therapeutics Research Laboratory, Deputy Head of Division of Clinical Trials and Epidemiological Sciences, and Director of Experimental Cancer Therapeutics Unit (Phase I Unit), National Cancer Centre Singapore
Associate Professor, Duke-NUS Medical School
Senior Clinician-Scientist, Genome Institute of Singapore
Adjunct Investigator, Singapore Immunology Network, SIgN

SY13 : Treatment of Driver Mutation Positive Lung Cancer, Except for EGFR and ALK (include Ras/RAF)




Paul A. Bunn

Paul A. Bunn
Professor and James Dudley Chair at the University of Colorado Cancer Center, USA

SY14 : Lung Cancer Treatment During the COVID-19 Pandemic




Alain C. Borczuk

Alain C. Borczuk
Professor of Pathology, Weill Cornell Medicine, USA

SY14 : Lung Cancer Treatment During the COVID-19 Pandemic




Solange Peters

Solange Peters
Chair and Professor, Medical Oncology Full Professor, University Hospital of Lausanne, Switzerland

WS4 : Immunotherapy for SCLC




Natasha Rekhtman

Natasha Rekhtman
Memorial Sloan Kettering Cancer Center, USA

WS10 : Neuroendocrine Tumors -Diagnosis and Treatment-